Non-Hodgkin Lymphoma Clinical Trials in Chicago, Illinois

9 studies are recruiting for non-hodgkin lymphoma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

   This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Robert H Lurie Cancer Center, Chicago, Illinois

   Locations

   11 in total

   Run by

   Miltenyi Biomedicine GmbH

   See if you can join NCT06116110 on ClinicalTrials.gov

2. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

   This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   36 in total

   Run by

   Lyell Immunopharma, Inc.

   See if you can join NCT07188558 on ClinicalTrials.gov

3. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

   This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

   Stage

   Not phased

   Ages

   Any age

   Site

   Northwestern Memorial Hospital, Chicago, Illinois

   Locations

   142 in total

   Run by

   Center for International Blood and Marrow Transplant Research

   See if you can join NCT01351545 on ClinicalTrials.gov

4. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

   This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

   Stage

   Phase 1

   Ages

   13 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   8 in total

   Run by

   Newave Pharmaceutical Inc

   See if you can join NCT04771572 on ClinicalTrials.gov

5. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

   This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.

   Stage

   Not phased

   Ages

   18 and older

   Site

   John H Stroger Jr Hospital of Cook County, Chicago, Illinois

   Locations

   467 in total

   Run by

   Wake Forest University Health Sciences

   See if you can join NCT06418204 on ClinicalTrials.gov

6. A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

   The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studie…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   38 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06876649 on ClinicalTrials.gov

7. A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

   Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stu…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   36 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06876662 on ClinicalTrials.gov

8. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

   This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern Memorial Hospital, Chicago, Illinois

   Locations

   13 in total

   Run by

   Carna Biosciences, Inc.

   See if you can join NCT05602363 on ClinicalTrials.gov

9. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Chicago, Illinois

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov